GAITHERSBURG, Md. -- BioVeris Corporation announced today that it completed an option agreement with Children's Hospital & Research Center at Oakland (CHRCO) for exclusive patent rights to a unique vaccine candidate for Neisseria meningitidis serogroup B, which causes meningitis. Under the agreement with CHRCO, the company acquired an option for exclusive rights to commercialize products for possible use in the prevention, diagnosis and treatment of disease caused by Neisseria meningitidis serogroup B.
The company and CHRCO also entered into a separate Sponsored Research Agreement under which the company will sponsor up to $800,000 of research at CHRCO over a two-year period aimed at developing a vaccine candidate. If the company exercises its option for exclusive rights, it will be required to pay a license issue fee, as well as milestones fees for initiating and completing human clinical trials and securing regulatory approvals, and royalties on product sales.
Source: BioVeris Corporation
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.